Trending...
- Official City of Long Beach Statement on the Passing of Former Mayor Robert "Bob" Foster
- Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
- Demystifying CBD & THC Levels: Ayah Labs' Easy-to-Follow Quantification Guide
Download
Overview of the TCRm-AFP/HLA-A*02 complex with the heavy and light chains of the TCRm (Graphic: Business Wire)
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a study in Nature's Scientific Reports entitled "Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma". The study was led by Dr. Cheng Liu, President and Chief Executive Officer of Eureka, Dr. Brian M. Baker and Dr. Moumita Dasgupta of the University of Notre Dame, and Dr. Chang Liu of The First Affiliated Hospital of Xi'an Jiaotong University.
T cell receptor mimic (TCRm) antibodies represent a novel approach to address one of the limitations of immunotherapy. Whereas traditional therapeutics antibodies are limited to targeting cell surface antigens, TCRm antibodies can target intracellular antigens presented by cell surface major histocompatibility complex (MHC) proteins, which enables the targeting of otherwise undruggable cancer antigens.
More on The Californer
Alpha-fetoprotein (AFP) is an intracellular antigen found in hepatocellular carcinoma (HCC), the predominant type of liver cancer. In a previous study, Eureka reported that an engineered TCRm targeting alpha-fetoprotein (AFP)-MHC complex can effectively redirect CAR-T cells against liver cancer cells.
In this study, the crystal structure showed the AFP-MHC targeting TCRm antibody binding directly over the center of the HLA protein. Unlike natural TCRs, the TCRm antibody interfaced with the AFP/HLA-A*02 complex by engaging the AFP peptide along its entire length, contacting most of the amino acids and interacting rigidly with the target complex. The significant interactions with the peptide likely confers the high affinity and specificity of the TCRm to AFP/HLA-A*02 observed in vitro and in animal studies when compared to natural TCRs. Moreover, no off-target effects were observed in the pre-clinical studies.
"TCR mimic antibodies represent a novel way to target the subset of cancer antigens found intracellularly," said Dr. Brian M. Baker, Coleman Professor of Life Sciences at the University of Notre Dame. "The details seen in the structural and biochemical data and the resulting high specificity and affinity for this TCRm could address some of the previous safety concerns about non-specific or off-target recognition in humans."
Eureka fused the binding domain of the TCRm to the γ and δ subunits of a TCR, and co-expressed a co-stimulatory molecule to create its proprietary ARTEMIS® T cell receptor. The engineered T cells showed potent killing activity against AFP-positive cancer cell lines in vitro and in vivo, with no off-target reactivity observed.
A first-in-human safety assessment of anti-AFP targeting ARTEMIS® T cells was conducted over a 17-month period on 6 HCC patients at the First Affiliated Hospital of Xi'an Jiaotong University in China. The anti-AFP targeting ARTEMIS® T cells demonstrated a favorable safety profile with no significant treatment-related adverse events. T cell expansion after infusions and a commensurate drop in serum AFP were detected in most patients in this study.
Eureka is currently conducting two clinical trials (ARYA-1 and ARYA-2) in the United States targeting AFP in patients with liver cancer using TCRm antibodies engineered onto ARTEMIS® T cells (ET140203). A third trial (ARYA-3) targets the GPC3 protein, also found on liver cancer cells, with ARTEMIS® T cells (ECT204). All three trials were granted Orphan Drug Designation by the U.S. Food and Drug Administration. For more information, visit www.eurekaconnectme.com.
More on The Californer
ABOUT EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. The company currently has two clinical programs, ET140203 (ARYA1 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04502082&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA1&index=8&md5=0a67d8c449710f0678a5b1dd8911b95f) for adults and ARYA2 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04634357&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA2&index=9&md5=200f387d28667f70d501dbae92acdde9) for pediatrics) and ECT204 (ARYA3 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04864054&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA3&index=10&md5=e2bbd769d5ff956241135bda81bee576)), in Phase I/II US trials in patients with advanced liver cancer.
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eurekatherapeutics.com&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=www.eurekatherapeutics.com&index=11&md5=a2baafafa8030a06973651d53156975d).
Contacts
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
Contacts
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com
Overview of the TCRm-AFP/HLA-A*02 complex with the heavy and light chains of the TCRm (Graphic: Business Wire)
- Overview of the TCRm-AFP/HLA-A*02 complex with the heavy and light chains of the TCRm (Graphic: Business Wire)
EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a study in Nature's Scientific Reports entitled "Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma". The study was led by Dr. Cheng Liu, President and Chief Executive Officer of Eureka, Dr. Brian M. Baker and Dr. Moumita Dasgupta of the University of Notre Dame, and Dr. Chang Liu of The First Affiliated Hospital of Xi'an Jiaotong University.
T cell receptor mimic (TCRm) antibodies represent a novel approach to address one of the limitations of immunotherapy. Whereas traditional therapeutics antibodies are limited to targeting cell surface antigens, TCRm antibodies can target intracellular antigens presented by cell surface major histocompatibility complex (MHC) proteins, which enables the targeting of otherwise undruggable cancer antigens.
More on The Californer
- Cleaner Communities Ahead: Countrywide Rental Launches Upgraded Portable Restrooms in Alton
- California: Governor Newsom proclaims Pearl Harbor Remembrance Day
- Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
- Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
- Filos Health Brings Mobile Blood Collection Services to California — Starting with San Francisco
Alpha-fetoprotein (AFP) is an intracellular antigen found in hepatocellular carcinoma (HCC), the predominant type of liver cancer. In a previous study, Eureka reported that an engineered TCRm targeting alpha-fetoprotein (AFP)-MHC complex can effectively redirect CAR-T cells against liver cancer cells.
In this study, the crystal structure showed the AFP-MHC targeting TCRm antibody binding directly over the center of the HLA protein. Unlike natural TCRs, the TCRm antibody interfaced with the AFP/HLA-A*02 complex by engaging the AFP peptide along its entire length, contacting most of the amino acids and interacting rigidly with the target complex. The significant interactions with the peptide likely confers the high affinity and specificity of the TCRm to AFP/HLA-A*02 observed in vitro and in animal studies when compared to natural TCRs. Moreover, no off-target effects were observed in the pre-clinical studies.
"TCR mimic antibodies represent a novel way to target the subset of cancer antigens found intracellularly," said Dr. Brian M. Baker, Coleman Professor of Life Sciences at the University of Notre Dame. "The details seen in the structural and biochemical data and the resulting high specificity and affinity for this TCRm could address some of the previous safety concerns about non-specific or off-target recognition in humans."
Eureka fused the binding domain of the TCRm to the γ and δ subunits of a TCR, and co-expressed a co-stimulatory molecule to create its proprietary ARTEMIS® T cell receptor. The engineered T cells showed potent killing activity against AFP-positive cancer cell lines in vitro and in vivo, with no off-target reactivity observed.
A first-in-human safety assessment of anti-AFP targeting ARTEMIS® T cells was conducted over a 17-month period on 6 HCC patients at the First Affiliated Hospital of Xi'an Jiaotong University in China. The anti-AFP targeting ARTEMIS® T cells demonstrated a favorable safety profile with no significant treatment-related adverse events. T cell expansion after infusions and a commensurate drop in serum AFP were detected in most patients in this study.
Eureka is currently conducting two clinical trials (ARYA-1 and ARYA-2) in the United States targeting AFP in patients with liver cancer using TCRm antibodies engineered onto ARTEMIS® T cells (ET140203). A third trial (ARYA-3) targets the GPC3 protein, also found on liver cancer cells, with ARTEMIS® T cells (ECT204). All three trials were granted Orphan Drug Designation by the U.S. Food and Drug Administration. For more information, visit www.eurekaconnectme.com.
More on The Californer
- KIKO NATION TOKEN (Official Release)
- Author Lee Jones Celebrates New Book With Free Kindle eBook Giveaway
- Melospeech updates proprietary MeloSuite platform to improve service delivery and response time
- GreenSTOP LA Unveils World's First Fully Automated Retail Store Powered by Revolutionary 4-Person Simultaneous Vending Technology
- Crypto Corner Shop, Built by Afghan Refugee, Set to Launch Soon!
ABOUT EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. The company currently has two clinical programs, ET140203 (ARYA1 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04502082&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA1&index=8&md5=0a67d8c449710f0678a5b1dd8911b95f) for adults and ARYA2 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04634357&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA2&index=9&md5=200f387d28667f70d501dbae92acdde9) for pediatrics) and ECT204 (ARYA3 (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04864054&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=ARYA3&index=10&md5=e2bbd769d5ff956241135bda81bee576)), in Phase I/II US trials in patients with advanced liver cancer.
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eurekatherapeutics.com&esheet=52799760&newsitemid=20220803005138&lan=en-US&anchor=www.eurekatherapeutics.com&index=11&md5=a2baafafa8030a06973651d53156975d).
Contacts
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Social Media Profiles
- Eureka Therapeutics (https://www.facebook.com/eurekatherapeutics)
- Eureka Therapeutics (https://twitter.com/EurekaThera)
- Eureka Therapeutics (https://www.linkedin.com/company/497678)
Contacts
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-318-9215
IR@eurekainc.com
Filed Under: Business
0 Comments
Latest on The Californer
- 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
- Affordable Luxury Jewellery Gifts for Christmas 2025: How Ermoleve Elevates Everyday Style
- Aketous Announces Through the Recursion: A Pop/Rock Odyssey of Consciousness, Technology, and Faith
- From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
- California: Helping survivors and victims of Stockton mass shooting
- Laurie McLennan and The McLennan Team Announces Strong Finish to 2025 With Notable Luxury Sales in La Quinta and Palm Desert
- City of Long Beach Launches Vacancy to Vibrancy Storefront Program to Revitalize Business Corridors
- Los líderes militares de California y México se unen para reforzar la resiliencia ante desastres y la seguridad fronteriza
- City of Long Beach Announces 2025-26 Winter Shelter and Inclement Weather Shelter
- "Great American Family to Premiere Christmas at Mistletoe Manor
- Demystifying CBD & THC Levels: Ayah Labs' Easy-to-Follow Quantification Guide
- Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
- Queen Sheba Ignites Global Movement with New TEDx Talk: "Reclaim They — The Pronoun of Genius"
- Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
- BrassTranscripts Publishes 13 Transcription Guides Covering Workflow-Specific Use Cases
- Unity to End Internal Support for Multiplay Game Server Hosting Service
- Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
- Rise Within Positions Itself as a Top Wellness Retreat Los Cabos for Transformational Travelers